Akio Niimi, of Nagoya City University, Japan, spoke to us at ERS 2019 in Madrid about a study of a novel P2X3 receptor antagonist S-600918 in patients with refractory chronic cough.
Questions
1. What are the most common causes of chronic cough? (0:05)
2. What is the mechanism of action of S-600918? (0:34)
3. Could you tell us about the recent Phase II study and its findings? (1:34)
4. How does S-600918 differ from other P2X3 receptor antagonists? (2:22)
5. Which patients are most likely to respond to this treatment and in whom is it contraindicated? (2:54)
Speaker disclosures: Akio Niimi has nothing to disclose in relation to this video interview.
touchRESPIRATORY.com is an independent information resource supporting physicians, clinicians and leading industry professionals in continuously developing their knowledge, effectiveness and productivity, via free-to-access content in multimedia formats.
Filmed at the European Respiratory Society (ERS) International Congress 2019, Madrid, Spain.
